|
Chemoprevention of arsenic-induced skin cancer
|
5R01CA107431-04
|
$1,511,506
|
$377,877
|
AHSAN, HABIBUL
|
UNIVERSITY OF CHICAGO
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-05
|
$234,166
|
$18,733
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
ATBC Study
|
Z01 CP010195-03031
|
$759,338
|
$37,967
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S5
|
$3,963,721
|
$39,637
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center Support Grant
|
3P30CA023074-30S6
|
$100,000
|
$1,000
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Children's Oncology Group Statistics and Data Center Grant
|
2U10CA098413-06
|
$5,717,149
|
$171,514
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Mechanisms in Perinatal Carcinogenesis
|
Z01 BC 005352
|
$546,189
|
$355,023
|
Anderson, Lucy
|
CCR (NCI)
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
Z01 CP010183-00580
|
$179,292
|
$17,929
|
Anderson, William
|
DCEG (NCI)
|
|
Swedish CER occupational study
|
Z01 CP010183-02050
|
$10,053
|
$2,011
|
Anderson, William
|
DCEG (NCI)
|
|
Extension of Radiotherapy Research
|
5P01CA006294-44
|
$1,516,143
|
$151,614
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
DF/HCC Renal Cancer SPORE
|
3P50CA101942-05S1
|
$1,165,299
|
$1,165,299
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-10
|
$128,678
|
$10,294
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
7R01CA077091-05
|
$338,540
|
$67,708
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-34
|
$417,899
|
$33,432
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
San Juan Minority - Based Community Clinical Oncology Program
|
2U10CA052667-18
|
$787,595
|
$7,876
|
BAEZ, LUIS
|
SAN JUAN HEALTH DEPARTMENT
|
|
Clinical Studies of Multidrug Resistance Reversal
|
Z01 BC 010620
|
$113,917
|
$45,567
|
Bates, Susan
|
CCR (NCI)
|
|
The role of Toll-like receptor 3 in overcoming cancer immunoediting
|
5K22CA122828-02
|
$162,047
|
$16,205
|
Bell, Jessica
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Eastern Cooperative Oncology Group Clinical Trials
|
5U10CA017145-33
|
$452,395
|
$36,192
|
BENSON, AL
|
NORTHWESTERN UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S2
|
|
$0
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S3
|
$49,998
|
$500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S4
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-44S5
|
|
$0
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-44
|
$11,641,774
|
$116,418
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
AACR-TREC-NIH Think Tank Conference: Energy Balance and Cancer; Mechanisms and Me
|
1R13CA134016-01
|
$10,000
|
$2,000
|
Berger, Nathan
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Geisinger Clinical Oncology Program
|
2U10CA035448-25
|
$599,474
|
$5,995
|
BERNATH, ALBERT
|
WEIS CENTER FOR RESEARCH-GEISINGER CLINC
|
|
Genetics of pediatric rhabdoid tumors
|
2R01CA046274-17A2
|
$266,860
|
$90,732
|
BIEGEL, JACLYN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Mechanisms of Renal Carcinogenesis
|
1R01CA131272-01A2
|
$235,720
|
$235,720
|
Block, Karen
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
|
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma
|
Z01 BC 011095
|
$72,501
|
$72,501
|
Bottaro, Donald
|
CCR (NCI)
|
|
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics
|
Z01 BC 011123
|
$108,751
|
$10,875
|
Bottaro, Donald
|
CCR (NCI)
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
Z01 BC 011124
|
$181,253
|
$181,253
|
Bottaro, Donald
|
CCR (NCI)
|
|
Late Effects of Treatment in Wilms Tumor Survivors and Offspring
|
5R01CA054498-17
|
$996,733
|
$996,733
|
BRESLOW, NORMAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein
|
1R01CA129387-01A2
|
$319,260
|
$319,260
|
Brugarolas, James
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
Cancer Center Support Grant
|
3P30CA046934-21S1
|
$728,250
|
$14,565
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
Cancer Center Support Grant
|
3P30CA046934-21S2
|
$73,150
|
$1,463
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
Cancer Center Support Grant
|
3P30CA046934-21S3
|
$85,992
|
$1,720
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
Cancer Center Support Grant
|
5P30CA046934-21
|
$3,604,774
|
$72,095
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
Inhibitors of Tyrosine Kinase-Dependent Signalling as Anti-Cancer Agents
|
Z01 BC 006198
|
$611,108
|
$458,331
|
Burke, Terrence
|
CCR (NCI)
|
|
SV40 Pathogenesis of Human Infections
|
5R01CA104818-05
|
$467,229
|
$140,169
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
|
MR-Image Guided Focused Ultrasound for Treatment of Liver and Renal Cancer
|
5R01CA121163-03
|
$656,041
|
$328,021
|
BUTTS, R
|
STANFORD UNIVERSITY
|
|
Methylation & Proteomics-Based Detection of Renal Cancer
|
5U01CA111242-05
|
$372,760
|
$372,760
|
CAIRNS, PAUL
|
FOX CHASE CANCER CENTER
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-33S1
|
$89,606
|
$896
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Innate Immunity: Elucidation and Modulation for Cancer Therapy
|
5P01CA095426-07
|
$2,003,446
|
$200,345
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
5P30CA016058-33
|
$3,753,703
|
$37,537
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Iowa case-control study of drinking water contaminants and other factors
|
Z01 CP010125-02130
|
$45,964
|
$7,814
|
Cantor, Kenneth
|
DCEG (NCI)
|
|
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies
|
2U01CA070095-14
|
$890,065
|
$80,106
|
CARDUCCI, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Analgesic Use and Kidney Cancer
|
1R03CA137764-01
|
$87,083
|
$87,083
|
CHO, EUNYOUNG
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
TRAIL Mediated Apoptosis in Renal Cell Carcinoma
|
5K08CA113452-04
|
$127,794
|
$127,794
|
CLARK, PETER
|
VANDERBILT UNIVERSITY
|
|
UMB/DFHCC Comprehensive Cancer Partnership Program
|
5U56CA118635-04
|
$429,888
|
$42,989
|
Colon-Carmona, Adan
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP OPERATIONS OFFICE
|
3U10CA021115-34S1
|
$61,182
|
$4,895
|
COMIS, ROBERT
|
FRONTIER SCI & TECHNOLOGY RSCH FDN, INC
|
Total relevant funding to Kidney Disease for this search: $43,431,683
|